| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients
|
Rimini, Margherita
|
|
|
18 |
1 |
p. 139-145
|
article
|
| 2 |
Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study
|
Koroki, Yosuke
|
|
|
18 |
1 |
p. 119-128
|
article
|
| 3 |
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
|
Brown, Gordon
|
|
|
18 |
1 |
p. 95-103
|
article
|
| 4 |
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
|
Ishihara, Hiroki
|
|
|
18 |
1 |
p. 159-168
|
article
|
| 5 |
Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
|
Lee, Arnold
|
|
|
18 |
1 |
p. 177
|
article
|
| 6 |
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
|
Huang, Yen-Hsiang
|
|
|
18 |
1 |
p. 179-180
|
article
|
| 7 |
Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast
|
John, Thomas
|
|
|
18 |
1 |
p. 1-8
|
article
|
| 8 |
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management
|
Safa, Houssein
|
|
|
18 |
1 |
p. 25-49
|
article
|
| 9 |
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy
|
Veccia, Antonello
|
|
|
18 |
1 |
p. 129-138
|
article
|
| 10 |
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
|
Neuzillet, Cindy
|
|
|
18 |
1 |
p. 51-76
|
article
|
| 11 |
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
|
Popat, Sanjay
|
|
|
18 |
1 |
p. 9-24
|
article
|
| 12 |
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
|
Kollmannsberger, Christian
|
|
|
18 |
1 |
p. 105-118
|
article
|
| 13 |
Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis
|
Song, Su Jeong
|
|
|
18 |
1 |
p. 147-158
|
article
|
| 14 |
Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma
|
Balaguer, Julia
|
|
|
18 |
1 |
p. 77-93
|
article
|
| 15 |
Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC
|
Nie, Tina
|
|
|
18 |
1 |
p. 169-176
|
article
|
Journal description